NIH conference. Aldose reductase and complications of diabetes.
Level 5 - mechanism / opinion, no new human data
Narrative review/conference summary discussing mechanistic and preclinical concepts without new human data.
PubMed 6203454 · doi:10.7326/0003-4819-101-1-82
What was done
This NIH conference summary reviewed the pathophysiological mechanisms linking aldose reductase and polyol accumulation (sorbitol, dulcitol) to diabetic ocular complications, including cataracts, delayed corneal wound healing, and retinal microvasculopathy, alongside the therapeutic potential of aldose reductase inhibitors.
What was found
No numerical results are reported in the abstract. Qualitatively, aldose reductase-mediated sorbitol accumulation leads to lens cortical fiber swelling and cataracts, as well as selective intramural pericyte loss in retinal capillary walls. Aldose reductase inhibitors were reported to prevent cataractogenesis and facilitate corneal wound healing, with ongoing randomized evaluation for retinopathy.
Why it matters
The paper outlines the mechanistic rationale for targeting aldose reductase to prevent diabetic microvascular and ocular disease, establishing the basis for clinical trials of inhibitors like sorbinil.
Limits
The abstract contains no quantitative data, sample size details, or primary clinical trial results. It represents narrative expert consensus and mechanistic reasoning rather than a systematic review or empirical clinical trial report.
Cited by
- supports In the lens of the eye, aldose reductase converts glucose to sorbitol, which acts as an osmolyte, causing lens fibers to swell and burst to form cataracts.
- supports Aldose reductase inhibitors effectively prevent cataractogenesis and treat complications of diabetes in rodent models.